Activist hedge fund builds stake in Ozempic-maker Novo Nordisk
Parvus shows interest in Danish drugmaker that is hunting for new chief following share price slump
Related reading
‘Not desperate’: Novo Nordisk’s Metsera miss puts strategy in spotlight
Ozempic maker’s new boss says he has a ‘fantastic pipeline’ after losing battle for biotech
Novo Nordisk shares plunge after profit warning over US weight-loss copycats
Share slide wipes more than €60bn off value of Danish maker of Ozempic and Wegovy
Novo Nordisk shares slide as Trump vows to cut Ozempic price
US administration is in negotiations over cost of Danish group’s best-selling obesity drug
Novo Nordisk calls for US import ban on key ingredient for obesity drug copycats
Danish group loses share in diabetes drugs to rivals, with first-half sales growth easing to 8%
Trump administration slashes Ozempic and Wegovy price for Medicare
US negotiates 71% cost reduction of Novo Nordisk’s obesity drugs for elderly Americans on government health insurance
Novo Nordisk gatecrashes Pfizer deal with $9bn bid for Metsera
Pfizer had struck deal in September to buy obesity-focused biotech